J&J : Data Suggest Esketamine More Effective Than Typical Treatments In Major Depressive Disorder

(RTTNews) - The new safety data from the ESCAPE-TRD Phase 3b study suggested Johnson & Johnson's Spravato or esketamine nasal spray was more tolerable and effective compared to quetiapine extended-release in adults with treatment-resistant major depressive disorder.

Janssen Pharmaceutical Companies of Johnson & Johnson noted that data on treatment-emergent adverse events or TEAEs suggested a more favourable tolerability profile in adults with treatment-resistant major depressive disorder (TRD) receiving esketamine nasal spray than quetiapine extended-release. Across all reported TEAEs experienced with esketamine nasal spray, 92.1 percent were transient and resolved the same-day compared to 12.1 percent of TEAEs experienced with quetiapine extended-release.

While more TEAEs were observed with esketamine NS than with quetiapine extended-release, a greater proportion of esketamine NS-treated patients (82.6 percent) reported a TEAE that resolved same-day day compared to quetiapine XR patients (15.5 percent).

Fewer esketamine NS-treated patients (53.6 percent) reported a TEAE that persisted for more than one day vs quetiapine XR-treated patients (74.7 percent) and TEAEs leading to treatment discontinuation were more frequent with quetiapine XR (11.0 percent) than with esketamine NS (4.2 percent).

For More Such Health News, visit rttnews.com